These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 36655691)
1. Synergistic effect of p53 gene/DOX intracellular delivery and P-gp inhibition by pullulan thiomers on cancer cells: S S P; M R R J Mater Chem B; 2023 Feb; 11(6):1365-1377. PubMed ID: 36655691 [TBL] [Abstract][Full Text] [Related]
2. Disulphide cross linked pullulan based cationic polymer for improved gene delivery and efflux pump inhibition. S PS; R RM Colloids Surf B Biointerfaces; 2016 Oct; 146():879-87. PubMed ID: 27459414 [TBL] [Abstract][Full Text] [Related]
3. Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy. Chen L; Ji F; Bao Y; Xia J; Guo L; Wang J; Li Y Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):418-429. PubMed ID: 27770912 [TBL] [Abstract][Full Text] [Related]
4. Redox sensitive cationic pullulan for efficient gene transfection and drug retention in C6 glioma cells. S S P; M R R Int J Pharm; 2017 Sep; 530(1-2):401-414. PubMed ID: 28779982 [TBL] [Abstract][Full Text] [Related]
5. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Zhan M; Yu D; Lang A; Li L; Pollock RE Cancer; 2001 Sep; 92(6):1556-66. PubMed ID: 11745235 [TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Lee TK; Lau TC; Ng IO Cancer Chemother Pharmacol; 2002 Jan; 49(1):78-86. PubMed ID: 11855756 [TBL] [Abstract][Full Text] [Related]
7. Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells. Lee SJ; Hwang SO; Noh EJ; Kim DU; Nam M; Kim JH; Nam JH; Hoe KL Exp Mol Med; 2014 Feb; 46(2):e76. PubMed ID: 24525822 [TBL] [Abstract][Full Text] [Related]
8. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery. Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555 [TBL] [Abstract][Full Text] [Related]
9. Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma. Chen CA; Lo CK; Lin BL; Sibley E; Tang SC Cancer Biol Ther; 2008 Feb; 7(2):303-9. PubMed ID: 18059187 [TBL] [Abstract][Full Text] [Related]
10. Fabrication of aminated poly(glycidyl methacrylate)-based polymers for co-delivery of anticancer drugs and the p53 gene. Li L; Tian H; He J; Zhang M; Li Z; Ni P J Mater Chem B; 2020 Oct; 8(41):9555-9565. PubMed ID: 33001126 [TBL] [Abstract][Full Text] [Related]
11. Cationised dextran and pullulan modified with diethyl aminoethyl methacrylate for gene delivery in cancer cells. Sherly MCD; Mr R; V S H Carbohydr Polym; 2020 Aug; 242():116426. PubMed ID: 32564849 [TBL] [Abstract][Full Text] [Related]
13. Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Xu Q; Leong J; Chua QY; Chi YT; Chow PK; Pack DW; Wang CH Biomaterials; 2013 Jul; 34(21):5149-62. PubMed ID: 23578555 [TBL] [Abstract][Full Text] [Related]
14. Investigation of the Sequential Actions of Doxorubicin and p53 on Tumor Cell Growth Via Branched Polyethylenimine-β-cyclodextrin Conjugates. Xie B; Peng J; Wang S; Zhang X; Nie H Ann Biomed Eng; 2016 Nov; 44(11):3372-3383. PubMed ID: 27122200 [TBL] [Abstract][Full Text] [Related]
15. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008 [TBL] [Abstract][Full Text] [Related]
16. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma. Ma Z; Guo D; Wang Q; Liu P; Xiao Y; Wu P; Wang Y; Chen B; Liu Z; Liu Q Theranostics; 2019; 9(10):2967-2983. PubMed ID: 31244936 [TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibitor NS-398 suppresses doxorubicin-induced p53 accumulation through inhibition of ROS-mediated Jnk activation. Kim J; Shim M Mol Carcinog; 2016 Dec; 55(12):2156-2167. PubMed ID: 26756900 [TBL] [Abstract][Full Text] [Related]
18. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. Wang S; Konorev EA; Kotamraju S; Joseph J; Kalivendi S; Kalyanaraman B J Biol Chem; 2004 Jun; 279(24):25535-43. PubMed ID: 15054096 [TBL] [Abstract][Full Text] [Related]